TMCnet News
Oncology Drug Report - Kadcyla - ado-trastuzumab emtansine - 2013-2015 Analysis & 2016-2021 Expectations - Research and MarketsResearch and Markets has announced the addition of the "Oncology Drug Report - Kadcyla - ado-trastuzumab emtansine - 2013-2015 Analysis; 2016-2021 Expectations" report to their offering. Kadcyla (ado-trastuzumab emtansine): Armed antibody is a comprehensive report on the first USFDA approved drug with antibody-drug conjugate for HER2-positive metastatic breast cancer treatment. Kadcyla falls in the monoclonal antibody, HER 2-targeted antibody-drug conjugate, class of drugs belonging to the targeted therapy. It is indicated for the treatment of HER2-positive metastatic breast cancer. The report provides basic information about the drug, covering all details such as brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events around the drug, news about Kadcyla, information on clinical studies of ongoing trials, number of clinical trials (by year and by phase), clinical study data about Kadcyla and other competing drugs and so on. The repot gives an analysis of the historical annual sales (from 2013 to Q3-2016), historical quarterly sales (Q1-2013 to Q3-2016), cumulative sales until date, Q3-2016 update and sales expectations (from 2016-2021). The analysis broadly indicates that the drug has seen a successful start and sales are likely to grow in the near future. We have highlighted key reasons for our expectations. All the historical as well as expected sales analysis is based on:
Key Topics Covered: 1. Basic Information 2. Approval timeline infographic (2012-2015) 3. Regulatory approval details (US, Europe, Japan and RoW) 4. Historical annual sales analysis (2013-2015, 2016E) 5. Historical quarterly sales analysis (Q1-2013 to Q3-2016) 6. Historical cumulative sales (2012 to Q3-2016) 7. Q3-2016 update 8. Sales expectations (2016E-2021E) 9. Ongoing trials of Kadcyla 10.Clinical studies outcome of Kadcyla in second-line treatment of HER2-positive advanced gastric cancer 11. List of key approved drugs in breast cancer 12. Clinical studies results of neratinib ExteNET trial 13. Event tracker 14. Clinical trials of Kadcyla (US) 15. News around Kadcyla Companies Mentioned
For more information about this report visit http://www.researchandmarkets.com/research/jdbf9b/oncology_drug
View source version on businesswire.com: http://www.businesswire.com/news/home/20170104005646/en/ |
